Tidal Trust II YieldMax MSTR Option Income Strategy ETF (ARCA: MSTY)

Ultime notizie per Tidal Trust II YieldMax MSTR Option Income Strategy ETF (ARCA:MSTY)

The Fund is an actively managed exchange-traded fund (ETF) that seeks current income while maintaining the opportunity for exposure to the share price (i.e., the price returns) of the common stock of MicroStrategy Incorporated (MSTR), subject to a limit on potential investment gains. The Fund will seek to employ its investment strategy as it relates to MSTR regardless of whether there are periods of adverse market, economic, or other conditions and will not seek to take temporary defensive positions during such periods. As further described below, the Fund uses a synthetic covered call strategy to provide income and exposure to the share price returns of MSTR, subject to a limit on potential investment gains as a result of the nature of the options strategy it employs.

First American Government Obligations Fund

YieldMax MSTR Option Income Strategy ETF

Specialty ETFs

ETFs

MSTR

Tidal Trust II YieldMax MSTR Option Income Strategy ETF

MSTY

NVDA

NVDY

ULTY

YBIT

YMAX

Il mercato premia chi sa scegliere. Strumenti finanziari innovativi che promettono entrate automatiche sicure.

Dividendi record: 5 ETF che ti faranno guadagnare mentre dormi

<ul>
<li>Key complex product approval in the Affordable Medicines segment this year</li>
<li>Commercial launch planned for third quarter of 2025</li>
</ul>
BRIDGEWATER, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") today announced the U.S. Food and Drug Administration (FDA) approval of prednisolone acetate ophthalmic suspension, 1% sterile which references Pred Forte&#xAE;. Pred Forte and its design are trademarks of Allergan, Inc., an AbbVie company. Launch of this product is planned for the third quarter of 2025.
Prednisolone acetate ophthalmic suspension, USP 1% is a sterile, topical anti-inflammatory agent for ophthalmic use and is indicated for treating steroid-responsive ocular inflammation.
According to IQVIA&#xAE; U.S. annual sales for prednisolone acetate ophthalmic suspension for the 12 months ended April 2025 were approximately $201 million.

News

AMRX

Amneal Pharma Announces FDA Approval For Prednisolone Acetate Ophthalmic Suspension; Product Launch Planned For Q3 2025

<a href="https://www.globenewswire.com/Tracker?data=LBI3dZa6X9pqujQP0b3qDtPb4A0mHsbh2E2iwg56HSneVkS2N_njEQ139AbTZxq29Owma6GCvT2xxrpv2eVaT-R-tw3wk31oqBVLm36QEwUEb479QrqH42YKThBSGmn0a4NgDlH5ZtJdTfbIJjGog37ydBMIGikjlEEtdKygzT5oB628atUzd0Fg2EDNJ7nUBQNR0WFS08dl0hLmOZ8HKi9Fyv2mqxBdpGLQEgE7zYblyog2TciMzcuQEAVWfKo0vWDLKUwk-zsgng-X7YgQvA==">BullFrog AI Holdings, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRG#NASDAQ">BFRG</a>, BFRGW))) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced a strategic collaboration with Sygnature Discovery, a leading UK-based contract research organization (CRO) specializing in drug discovery. Through this collaboration, Sygnature will introduce BullFrog Data Networks&#x2122;—BullFrog's proprietary AI-driven data insights platform powered by the bfLEAP&#x2122; engine—to Sygnature's global client base of relevant biopharma companies.
The collaboration marks a significant commercial milestone for BullFrog AI and is expected to greatly accelerate brand recognition and user uptake to generate between $15-$30 million in revenue for BullFrog AI through 2028.

BFRG

BullFrog AI Announces Strategic Collaboration With Sygnature Discovery To Expand AI Platform Reach, Projecting Up To $30M Revenue By 2028

Contracts

JRSH

Jerash Holdings Secures Order From An Omnichannel Retain Corporation; Order Consists Over 3M Pairs Of Shorts

Oceaneering International, Inc. ("Oceaneering") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OII#NYSE">OII</a>) announced today that its Offshore Projects Group ("OPG") segment has entered into a vessel services agreement with a major operator for use of the MPSV Harvey Deep Sea.
The MPSV Harvey Deep Sea, currently chartered by Oceaneering through February 2027, is equipped with two Oceaneering Millennium work class remotely operated vehicles. It is expected to be used by the operator to perform subsea inspection, maintenance, and repair (IMR) and installation services in the Gulf of Mexico.

Oceaneering Secures Vessel Services Agreement For 'Harvey Deep Sea' To Support Subsea Operations

On May 9, 2025, Neo-Concept International Group Holdings Ltd (the "Company") held the Company's Extraordinary General Meeting (the "EGM") , amongst which a share consolidation (the "Share Consolidation") was approved by the shareholders, whereby every five issued and unissued shares (namely, both class A ordinary shares of par value US$0.0000625 each and class B ordinary shares of par value US$0.0000625 each) in the share capital of the Company be consolidated into one (1) share of par value US$0.0003125 each (the "Share Consolidation") so that the authorized share capital of the Company shall be changed from US$50,000 consisting of 800,000,000 shares of par value US$0.0000625 each comprised of 780,000,000 class A ordinary shares of par value US$0.0000625 each and 20,000,000 class B ordinary shares of par value US$0.0000625 each to US$50,000 consisting of 160,000,000 shares of par value US$0.0003125 each comprised of 156,000,000 class A ordinary shares of par value US$0.0003125 each and 4,000,000 class B ordinary shares of par value US$0.0003125 each. The Share Consolidation was to be effective from such date and time to be determined by the board of directors of the Company which in any event shall not be later than 1 July 2025.
The Share Consolidation shall be reflected with the Nasdaq Capital Market and in the marketplace at the open of business on June 16, 2025, whereupon the Class A Ordinary Shares will continue trading under the symbol "NCI" and under the new CUSIP Number of G6421C120.

Neo-Concept International Approves 5-To-1 Share Consolidation At EGM

Government

Regulations

MEOH

Methanex Says All Regulatory Approvals To Close Acquisition Of OCI Global's Methanol Business Have Been Obtained

DeFi Development Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFDV#NASDAQ">DFDV</a>) (the "Company" or "DeFi Dev Corp."), the first U.S. public company with a treasury strategy built to accumulate and compound Solana ("SOL"), today announced it has entered into a share purchase agreement (the "ELOC") with RK Capital Management LLC ("RK Capital").
Under the ELOC, the Company will have the right, but not the obligation, to issue and sell up to $5 billion in shares of its common stock to RK Capital, subject to customary conditions, including an effective registration statement for resale. The Company plans to file a registration statement on Form S-1 as soon as practicable to enable access to this facility.
The proceeds from the ELOC are expected to support continued accumulation of SOL and accelerate growth in SOL per share. Unlike other equity offerings, an ELOC enables DeFi Development Corp. to raise capital gradually, when it's strategically advantageous, rather than locking in one-time pricing during volatile markets.
The Company also filed a Form S-1 to register securities issued in prior unregistered offerings on June 11, 2025.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

DFDV

DeFi Development Corp. Secures $5B Equity Facility With RK Capital To Fuel Solana Accumulation Strategy

<h3>Gainers</h3>
<ul>
<li>Greenlane Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares moved upwards by 64.9% to $0.01 during Thursday's pre-market session. The market value of their outstanding shares is at $12.9 million. </li>
<li>ZHONGCHAO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCMD#NASDAQ">ZCMD</a>) shares moved upwards by 16.34% to $1.21. The company's market cap stands at $30.5 million. </li>
<li>QVC Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QVCGA#NASDAQ">QVCGA</a>) stock moved upwards by 10.96% to $3.44. The market value of their outstanding shares is at $27.7 million. </li>
<li>Newegg Commerce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEGG#NASDAQ">NEGG</a>) shares increased by 9.61% to $11.74. The market value of their outstanding shares is at $228.6 million. </li>
<li>Jerash Holdings (US) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JRSH#NASDAQ">JRSH</a>) stock increased by 7.3% to $3.38. The market value of their outstanding shares is at $41.5 million. </li>
<li>Solid Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDP#NASDAQ">SLDP</a>) stock moved upwards by 7.21% to $2.0. The company's market cap stands at $359.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>INNEOVA Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INEO#NASDAQ">INEO</a>) stock fell 18.5% to $1.45 during Thursday's pre-market session. The market value of their outstanding shares is at $14.3 million. </li>
<li>GameStop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) shares declined by 16.08% to $23.96. The company's market cap stands at $10.7 billion. The company's, Q1 earnings came out 2 days ago. </li>
<li>FAT Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAT#NASDAQ">FAT</a>) shares declined by 10.57% to $2.37. The market value of their outstanding shares is at $42.2 million. </li>
<li>Oxford Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXM#NYSE">OXM</a>) shares declined by 9.06% to $45.5. The company's market cap stands at $714.3 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Koss (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOSS#NASDAQ">KOSS</a>) stock fell 8.63% to $5.06. The market value of their outstanding shares is at $47.4 million. </li>
<li>QuantaSing Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSG#NASDAQ">QSG</a>) shares declined by 8.38% to $11.05. The company's market cap stands at $564.7 million. As per the news, the Q3 earnings report came out 4 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

GNLN

INEO

KOSS

NEGG

QVCGA

SLDP

ZCMD

12 Consumer Discretionary Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock increased by 115.2% to $0.02 during Thursday's pre-market session. The company's market cap stands at $8.0 million. </li>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) stock rose 31.32% to $14.59. The market value of their outstanding shares is at $379.5 million. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) stock moved upwards by 19.31% to $1.73. The company's market cap stands at $56.2 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares rose 15.15% to $2.28. The market value of their outstanding shares is at $2.3 million. </li>
<li>Wellgistics Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGRX#NASDAQ">WGRX</a>) stock moved upwards by 14.78% to $1.63. The market value of their outstanding shares is at $117.1 million. </li>
<li>TherapeuticsMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXMD#NASDAQ">TXMD</a>) stock rose 11.66% to $1.34. The company's market cap stands at $15.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Intensity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>) shares decreased by 48.7% to $0.3 during Thursday's pre-market session. The market value of their outstanding shares is at $5.4 million. </li>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) stock decreased by 39.93% to $0.67. </li>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) stock decreased by 26.68% to $0.44. The market value of their outstanding shares is at $4.8 million. </li>
<li>Jupiter Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JUNS#NASDAQ">JUNS</a>) shares decreased by 22.62% to $1.54. The market value of their outstanding shares is at $50.9 million. </li>
<li>Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) stock declined by 22.28% to $29.31. The company's market cap stands at $214.6 million. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) shares decreased by 13.83% to $0.32. The company's market cap stands at $1.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HCTI

HSDT

INTS

JUNS

KLTO

LIMN

NIVF

NUWE

TNXP

TXMD

VTAK

WGRX

12 Health Care Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Volato Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SOAR#AMEX">SOAR</a>) shares increased by 62.7% to $3.53 during Thursday's pre-market session. The market value of their outstanding shares is at $6.7 million. </li>
<li>Graphjet Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTI#NASDAQ">GTI</a>) stock rose 20.52% to $0.08. The market value of their outstanding shares is at $11.4 million. </li>
<li>Babcock &amp; Wilcox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BW#NYSE">BW</a>) stock increased by 8.19% to $1.32. The company's market cap stands at $129.8 million. </li>
<li>Arrive AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAI#NASDAQ">ARAI</a>) stock rose 5.99% to $9.01. The market value of their outstanding shares is at $297.2 million. </li>
<li>Founder Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGL#NASDAQ">FGL</a>) shares rose 4.85% to $1.08. The market value of their outstanding shares is at $20.9 million. </li>
<li>Captivision (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPT#NASDAQ">CAPT</a>) stock rose 4.8% to $1.31. The market value of their outstanding shares is at $42.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Stem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>) shares declined by 13.1% to $0.53 during Thursday's pre-market session. The company's market cap stands at $87.4 million. </li>
<li>Dragonfly Energy Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFLI#NASDAQ">DFLI</a>) stock declined by 12.26% to $0.35. The market value of their outstanding shares is at $3.2 million. </li>
<li>Urban-gro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares decreased by 9.57% to $0.33. The company's market cap stands at $4.1 million. </li>
<li>WANG &amp; LEE Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>) shares declined by 8.74% to $0.08. The company's market cap stands at $1.7 million. </li>
<li>ATIF Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBAI#NASDAQ">ZBAI</a>) shares fell 8.58% to $0.42. The company's market cap stands at $7.2 million. The company's, Q3 earnings came out 4 days ago. </li>
<li>Samfine Creation Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFHG#NASDAQ">SFHG</a>) shares decreased by 8.52% to $0.74. The company's market cap stands at $15.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARAI

CAPT

DFLI

SFHG

SOAR

STEM

UGRO

WLGS

ZBAI

12 Industrials Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Creative Global Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTL#NASDAQ">CGTL</a>) shares increased by 53.9% to $1.42 during Thursday's pre-market session. The market value of their outstanding shares is at $30.4 million. </li>
<li>Applied Optoelectronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAOI#NASDAQ">AAOI</a>) shares moved upwards by 13.41% to $18.51. The company's market cap stands at $1.0 billion. </li>
<li>Trident Digital Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDTH#NASDAQ">TDTH</a>) stock rose 11.58% to $0.36. The market value of their outstanding shares is at $23.0 million. </li>
<li>Oracle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) shares moved upwards by 8.68% to $191.7. The market value of their outstanding shares is at $537.5 billion. As per the news, the Q4 earnings report came out yesterday. </li>
<li>AXT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXTI#NASDAQ">AXTI</a>) shares increased by 8.58% to $2.15. The company's market cap stands at $98.0 million. </li>
<li>Verb Technology Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERB#NASDAQ">VERB</a>) shares increased by 7.33% to $8.71. The company's market cap stands at $12.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Castellum (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CTM#AMEX">CTM</a>) stock fell 14.6% to $1.17 during Thursday's pre-market session. The company's market cap stands at $100.7 million. </li>
<li>Karooooo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KARO#NASDAQ">KARO</a>) stock fell 14.18% to $51.09. The market value of their outstanding shares is at $1.5 billion. </li>
<li>FOXO Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/FOXO#AMEX">FOXO</a>) shares decreased by 10.24% to $0.27. The market value of their outstanding shares is at $1.7 million. </li>
<li>Movano (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOVE#NASDAQ">MOVE</a>) stock decreased by 8.7% to $0.72. The company's market cap stands at $5.0 million. </li>
<li>XTI Aerospace (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTIA#NASDAQ">XTIA</a>) shares decreased by 6.74% to $4.71. The company's market cap stands at $29.6 million. </li>
<li>Sonim Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONM#NASDAQ">SONM</a>) stock decreased by 6.2% to $1.06. The market value of their outstanding shares is at $10.9 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AAOI

AXTI

CGTL

FOXO

KARO

MOVE

ORCL

SONM

TDTH

VERB

XTIA

12 Information Technology Stocks Moving In Thursday's Pre-Market Session

Rezolve Ai (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLV#NASDAQ">RZLV</a>), the company reinventing retail through real-time AI-driven consumer engagement, today announced that it has secured more than $70 million in Annual Recurring Revenue (ARR) months ahead of schedule putting the company on a clear trajectory to surpass its targeted $100 million ARR before the close of 2025.
This achievement marks a pivotal moment in Rezolve Ai's growth journey, having scaled from a standing start earlier this year and now backed by strategic go-to-market and platform integrations with both Microsoft and Google. These alliances have accelerated Rezolve Ai's global reach and commercial scale, reinforcing its position as a leading AI platform purpose-built for commerce.

RZLV

Rezolve Ai Surpasses $70M ARR Ahead Of Schedule, On Track To Exceed $100M Target By End Of 2025

Amneal Receives FDA Approval For Prednisolone Acetate Ophthalmic Suspension

Researchers at the John Innes Centre (JIC) have discovered a genetic mutation with the potential to enhance nutrient uptake and reduce the need for artificial fertilizers
Cibus and JIC have agreed on a collaboration with the potential to introduce the trait into several commercial crops
Cibus previously announced the successful editing of Canola plants with this mutation and looks forward to further testing and trait validation
SAN DIEGO, June 12, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. ("Cibus" or the "Company") (NASDAQ:<a href="https://www.benzinga.com/stock/CBUS#NASDAQ">CBUS</a>), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today confirmed its continuing collaboration with the John Innes Centre (JIC). Cibus applauds the JIC breakthrough discovery, published earlier this year in the journal Nature, of a biological mechanism that makes plant roots more welcoming to beneficial soil microbes. Cibus and JIC have been collaborating to translate JIC's discovery into a nutrient use efficiency (NUE) trait for a number of crops, including canola/oilseed rape. If successfully developed, the NUE trait would lead to improved nutrient uptake thereby reducing the use of nitrate and phosphate fertilizers without compromising yields.

CBUS

Cibus Confirms Continuing Collaboration With John Innes Centre To Revolutionize Fertilizer Use In Farming

La Rosa Holdings Corp. (NASDAQ:&nbsp;LRHC) ("La Rosa" or the "Company"), a real estate and PropTech company, &nbsp;today announced that it has entered into a non-binding Letter of Intent ("LOI") with MiiX Financial Holdings Trust ("MiiX') to jointly implement and distribute MiiX's proprietary residential financing solutions for all credit levels across La Rosa's network of approximately 2,900 agents and all of its listings.
The partnership is intended to establish a long-term strategic alliance between the two companies, centered on MiiX's groundbreaking platform that eliminates traditional credit requirements and provides accessible homeownership solutions for buyers of all income and credit levels. The platform also introduces advanced real estate monetization tools capable of enabling same-day property purchasing, trading, settlement, and recordings similar to the speed and efficiency of financial markets.
Under the LOI, La Rosa and MiiX will work toward a definitive agreement that is expected to include the following key terms:
<ul>
<li>La Rosa and/or a newly formed division or subsidiary, will become the exclusive real estate partner for MiiX's proprietary financing technology platform.</li>
<li>MiiX will integrate its products directly into La Rosa's agent workflows and property listings, potentially creating added value for both agents and homebuyers.</li>
<li>All La Rosa listings will feature access to financing solutions, aimed at increasing access to homeownership and accelerating the efficiency of real estate transactions.</li>
</ul>
The parties will collaboratively determine the operational structure and deployment timeline as they advance toward a definitive agreement.

LRHC

La Rosa Holdings Signs LOI With MiiX Financial To Deploy Inclusive Home Financing Platform Across Network

Upon completion of the acquisition, M2i Global will receive common shares of Volato Group stock such that M2i Global will own approximately 90% of the total issued and outstanding shares of common stock of Volato Group on an as-converted and fully diluted basis (excluding any outstanding public warrants for SOAR common stock) and the current shareholders of Volato Group will own approximately 10% of the total issued and outstanding shares of SOAR common stock on an as-converted and fully diluted basis (excluding any outstanding public warrants for SOAR common stock). Based on current market prices, this structure represents an increase in value for SOAR shareholders while aligning MTWO with an NYSE American listing and public equity currency.
 &nbsp;

Volato Group To Acquire M2i Global; M2i Global To Receive Volato Common Shares Such That M2i Will Own ~90% Of Total Issued And Outstanding Shares

~ Andrew J. Trontis, MD from Progressive Spine and Orthopaedics, (Englewood, NJ) Completes Initial Case Series ~
LOS GATOS, CA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / June 12, 2025 / Tenon Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today announced the completion of an initial case series utilizing the Catamaran&#xAE; SI Joint Fusion System (the "Catamaran") to immobilize &amp; stabilize the SI Joint providing added support at the base of a lumbar or thoracolumbar fusion. The case series was completed by Andrew J. Trontis, MD from Progressive Spine &amp; Orthopaedics in Englewood, New Jersey. As <a href="https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/tenon-medicalr-announces-fda-clearance-of-catamaranr-si-joint-fusion--1004697">announced previously</a> by the Company, the Catamaran recently received an expanded indication for use from the U.S. Food and Drug Administration (FDA). The Catamaran is now approved to augment immobilization and stabilization of the SI joint for patients undergoing sacropelvic fixation as part of a lumbar fusion.

Biotech

General

TNON

Tenon Medical Announces Completion Of Initial Case Series Using Catamaran SI Joint Fusion System

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer recommended buying Union Pacific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>). &#8220;I think it's a <a href="https://www.benzinga.com/quote/UNP/analyst-ratings">really good stock to own,&#8221; he added.</a>
Supporting his view, BofA Securities analyst Ken Hoexter, on May 16, maintained Union Pacific with a Buy rating and raised the price target from $256 to $262.
&#8220;I'm getting tired of the orphan drug model,&#8221; Cramer said when asked about BioMarin Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>). &#8220;I don't think it works now.&#8221;
As per the recent news, BioMarin, on May 16, agreed to acquire Inozyme for $4.00 per share in all-cash transaction for total consideration of about $270 million.
Cramer said he likes the model of ARS Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRY#NASDAQ">SPRY</a>). &#8220;It's a great flier. Someone needs that technology, someone's going to pay for it,&#8221; he added.
Lending support to his choice, ARS Pharmaceuticals, on May 14, posted better-than-expected sales for the first quarter.
&#8220;I was prepared for disappointment and I got it,&#8221; Cramer said when asked about GitLab Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLB#NASDAQ">GTLB</a>). &#8220;I just do not want enterprise software. I think they're all too expensive.&#8221;
Supporting his view, GitLab, on June 10, issued second-quarter sales guidance with its midpoint below estimates. GitLab sees second-quarter adjusted EPS of between 16 and 17 cents, versus the 16 cent estimate, and revenue of between $226 million and $227 million, versus the $227.16 million analyst estimate.
The Mad Money host said he would buy NuScale Power Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) if it does an offering here. &#8220;I'd wait for the stock offering after what happened with Oklo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) tonight,&#8221; he added.
UBS analyst Jon Windham, on May 29, maintained NuScale Power with a Neutral and raised the price target from $17 to $34.
Price Action:
<ul class="wp-block-list">
<li>BioMarin Pharmaceutical shares fell 0.6% to settle at $57.16 on Wednesday.</li>
<li>NuScale Power shares jumped 20.4% to close at $41.60.</li>
<li>Union Pacific fell 0.4% to settle at $225.72 on Wednesday.</li>
<li>GitLab shares fell 10.6% to close at $43.37.</li>
<li>ARS Pharmaceuticals shares fell 2.4% to settle at $14.34.</li>
</ul>
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45882911/top-2-consumer-stocks-that-may-plunge-in-june">Top 2 Consumer Stocks That May Plunge In June</a></li>
</ul>
Image: Shutterstock

Analyst Color

Long Ideas

Media

Trading Ideas

BMRN

GTLB

OKLO

SPRY

Jim Cramer Is All Aboard Union Pacific, But Shows No Love For Orphan Drugs

Telsey Advisory Group analyst Dana Telsey maintains J.Jill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JILL#NYSE">JILL</a>) with a Market Perform and lowers the price target from $21 to $17.

Price Target

Analyst Ratings

JILL

Telsey Advisory Group Maintains Market Perform on J.Jill, Lowers Price Target to $17

<a href="https://www.globenewswire.com/Tracker?data=CxrsxD5uGK6ynUyVQZ_galOWTmNxxCUp-60-pQD6jcA9AEhoBEUQqJBFSy8g4OvMjFfDGntItw4JT0T6SPs6f6_UO2EnigIcdNFqShdUezE=">AIM ImmunoTech Inc.</a> (OTC:<a href="https://www.benzinga.com/stock/AIMID#OTC">AIMID</a>) (NYSE:<a href="https://www.benzinga.com/stock/AIM#NYSE">AIM</a>) ("AIM" or the "Company") today announced that the staff of NYSE Regulation has withdrawn its delisting determination and will be lifting the trading suspension of the Company's common stock on the NYSE American. The NYSE Regulation staff determined that the Company's common stock was now trading above the threshold of low selling price issues as further defined by Section 1003(f)(v) of the NYSE American Company Guide. AIM's common stock is expected to resume trading on the NYSE American on Tuesday, June 17, 2025, under the symbol "AIM" and CUSIP 00901B303.

AIMI

NYSE Regulation Withdraws Delisting Determination, AIM ImmunoTech Trading To Resume On June 17, 2025

Comments

Tidal Trust II YieldMax MSTR Option Income Strategy ETF

Notizie

Ultime notizie per Tidal Trust II YieldMax MSTR Option Income Strategy ETF (ARCA:MSTY)

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO